Dr. Scott Kahn, CIO of Illumina, presents challenges and progress on big data solutions and its impact on scientific research at the 2013 Genome Informatics Alliance meeting.
Rakesh Nagarajan, MD, PhD and founder of PierianDx, discusses the rise of precision medicine programs and makes the business case for healthcare institutions to build their own clinical NGS testing programs.
Optimizing the Output of Your Molecular Pathology LaboratoryJosh Forsythe
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming - planning, assay design, validation, clinical lab workflow, informatics, and interpretation.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using "Actionable Intelligence" - a combination of machine learning and human expertise to achieve clinically actionable insights.
Webinar analyzing complex genomic variants in somatic cancer Lisa Owen
Next generation sequencing (NGS) technologies facilitate the accurate detection of genetic and genomic variants. Yet the process of analyzing and classifying more complex alterations remains challenging.
In this slide deck, which is a companion to the webinar presented on February 21, 2019 and located here (https://www.pieriandx.com/analyzingcomplexgenomicvariants) you’ll learn how to analyze complex genomic alterations, such as gene fusions, splice-site mutations, and co-occurring variants within the context of somatic cancer.
Is insourcing NGS testing worth it?
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.
In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?
Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.
In this webinar you will learn:
How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
How to make a strong business case for in-house NGS testing.
Challenges your institution is likely to face by insourcing.
Blueprints for overcoming these challenges, including reimbursement.
Dr. Randy Prather - Porcine Reproductive and Respiratory Syndrome Virus Resis...John Blue
Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs - Dr. Randy Prather, University of Missouri, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Rakesh Nagarajan, MD, PhD and founder of PierianDx, discusses the rise of precision medicine programs and makes the business case for healthcare institutions to build their own clinical NGS testing programs.
Optimizing the Output of Your Molecular Pathology LaboratoryJosh Forsythe
If you are a clinical lab looking to build or accelerate your NGS testing capability where do you start? The components of success can be overwhelming - planning, assay design, validation, clinical lab workflow, informatics, and interpretation.
During this one-hour webinar, BG Jones, SVP of Business Development for PierianDx, who has 23 years of experience in healthcare IT and genomics technology, will demonstrate how to pull it all together using "Actionable Intelligence" - a combination of machine learning and human expertise to achieve clinically actionable insights.
Webinar analyzing complex genomic variants in somatic cancer Lisa Owen
Next generation sequencing (NGS) technologies facilitate the accurate detection of genetic and genomic variants. Yet the process of analyzing and classifying more complex alterations remains challenging.
In this slide deck, which is a companion to the webinar presented on February 21, 2019 and located here (https://www.pieriandx.com/analyzingcomplexgenomicvariants) you’ll learn how to analyze complex genomic alterations, such as gene fusions, splice-site mutations, and co-occurring variants within the context of somatic cancer.
Is insourcing NGS testing worth it?
Dartmouth-Hitchcock has experienced nearly 40% savings by bringing NGS testing in-house. A recent AMP study using non-small cell lung cancer as an example cites $2.7 million in anticipated savings.
In-house NGS testing is the foundation of any modern precision medicine program. It can have a profound effect on patient care. And, as these examples show, a strong business case can be made.
How have Dartmouth-Hitchcock and other progressive institutions been so successful despite myriad challenges?
Join us for a webinar on May 31st at 12pm ET as Eric Loo, MD (Dartmouth-Hitchcock) and Rakesh Nagarajan, MD, PhD (PierianDx) explore answers to this question and more.
In this webinar you will learn:
How recent precision medicine trends are driving strong market growth for clinical NGS and other complex molecular testing.
How to make a strong business case for in-house NGS testing.
Challenges your institution is likely to face by insourcing.
Blueprints for overcoming these challenges, including reimbursement.
Dr. Randy Prather - Porcine Reproductive and Respiratory Syndrome Virus Resis...John Blue
Porcine Reproductive and Respiratory Syndrome Virus Resistant Pigs - Dr. Randy Prather, University of Missouri, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
Paolo Liberati, Recuperator Technical Department - R&D and Andrea Pagan, CAREL Application Manager - HVAC Commercial at Chillventa eSpecial 2020.
Exploring CAREL's solutions for Air Handling Units able to ensure Health and Safety in critical applications, while remaining highly-efficient in terms of energy consumption.
An Exploration of Clinical Workflows in VarSeqGolden Helix
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
Before assessing the clinical significance of a somatic mutation, one must determine if the mutation is likely to be a driver mutation (i.e. a mutation that provides a selective growth advantage, thereby promoting cancer development). To aid clinicians in this process, VSClinical provides an oncogenicity scoring system, which uses a variety of metrics to classify a given somatic mutation into one of the following categories: oncogenic, likely oncogenic, benign, likely benign, or uncertain significance. This scoring system is heavily inspired by the ACMG Guidelines for the interpretation of germline mutations but has several important differences to make it more applicable in the context of somatic variant interpretation.
Our oncogenicity scoring system relies on an additive point system in which points are assigned to a given variant based on several criteria. Many of the criteria are shared by the ACMG Guidelines for germline variant interpretation, such as population frequency information, variant effect on protein function, and nearby pathogenic variants in catalogs such as ClinVar. However, other criteria are specific to the world of somatic variant interpretation. These include the variant’s presence in somatic catalogs such as COSMIC, the effect of other known oncogenic variants in the same gene, and the variant’s presence in known cancer hotspots or active binding sites. These criteria are combined by summing over the scores for all applicable scoring criteria. Scores exceeding 3 indicate an oncogenic or likely oncogenic classification, while scores falling below -3 indicate a benign or likely benign classification.
In this webcast, we discuss how each of these scoring criteria are combined to obtain an oncogenicity classification. This includes a discussion of the considerations taken into account during the development of this scoring system and a detailed analysis of several example mutations to illustrate the system in practice.
CNV Annotations: a crucial step in your variant analysisGolden Helix
Since the development of our NGS-based CNV solutions for VarSeq and SVS, we've generated a long list of content demonstrating simple workflows to help isolate clinically relevant events for a given sample. However, it's just as important to talk about the exclusionary filters that help remove any extraneous CNVs from the analysis.
Golden Helix stands alone in our delivery of multiple methods for filtering down to top-quality, rare, and clinically relevant variants. This webcast will focus on the application of the various CNV annotations, discussing their purpose and usability in quickly removing CNVs with high-population frequency, duplicated regions inherent to the human genome, benign events, and events known in healthy individuals.
Please join us in an exploration of VarSeq's unique CNV annotation capabilities to see how users can overcome the challenges of NGS-based CNV detection.
What will you learn in this webcast?
Initial assessment of sample and CNV event quality
General review and understanding of various CNV annotations in VarSeq
The application of CNV annotations to eliminate common and benign CNVs
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline WorkflowGolden Helix
Golden Helix has been in close communication with the publishers of the ACMG guidelines and the ClinGen group to receive expert advice on how to interpret CNVs called on NGS data. These guidelines provide a robust set of rules for interpreting intragenic deletions and duplications, which is summarized into an intricate decision tree that is broken down into 80 distinct criteria. This complexity is further compounded by many important caveats, exceptions, and considerations known to many in the CNV clinical workspace but are not mentioned in the published guidelines. Fortunately, Golden Helix has spent long hours reading the guidelines, watching the webinars, reading the supplementary material, and working with collaborators to develop a comprehensive workflow to guide you through your clinical interpretation of CNVs. Herein, we are excited to cover more details into this novel ACMG CNV guideline interpretation workflow and demonstrate how intuitive this feature can be for your clinical pipeline. Specifically, we will cover:
The intricacies of the ACMG CNV Sample auto classifier
Unique annotations and algorithms
Adjustable metrics and parameters in the VSClinical ACMG interface
Rendering clinical reports
Why should your accounting or advisory firm do blogging? Where does blogging fit into your overall marketing approach? How do you measure its effectiveness? What results are firms getting?
Everyone has a skeleton in the closet, even most famous #writers have, no matter how many bestsellers they wrote or prizes they won.
For example, if you have read only the works of this famous writer, you never guess that…
Check out our #infographic and related blog post for more details goo.gl/1TP8FR
An invited talk for Lilly's Global IT Seminar Meeting In November 2016 on the subject of data, machine learning, AI, semantic web, text mining and spinach!
Paolo Liberati, Recuperator Technical Department - R&D and Andrea Pagan, CAREL Application Manager - HVAC Commercial at Chillventa eSpecial 2020.
Exploring CAREL's solutions for Air Handling Units able to ensure Health and Safety in critical applications, while remaining highly-efficient in terms of energy consumption.
An Exploration of Clinical Workflows in VarSeqGolden Helix
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
Before assessing the clinical significance of a somatic mutation, one must determine if the mutation is likely to be a driver mutation (i.e. a mutation that provides a selective growth advantage, thereby promoting cancer development). To aid clinicians in this process, VSClinical provides an oncogenicity scoring system, which uses a variety of metrics to classify a given somatic mutation into one of the following categories: oncogenic, likely oncogenic, benign, likely benign, or uncertain significance. This scoring system is heavily inspired by the ACMG Guidelines for the interpretation of germline mutations but has several important differences to make it more applicable in the context of somatic variant interpretation.
Our oncogenicity scoring system relies on an additive point system in which points are assigned to a given variant based on several criteria. Many of the criteria are shared by the ACMG Guidelines for germline variant interpretation, such as population frequency information, variant effect on protein function, and nearby pathogenic variants in catalogs such as ClinVar. However, other criteria are specific to the world of somatic variant interpretation. These include the variant’s presence in somatic catalogs such as COSMIC, the effect of other known oncogenic variants in the same gene, and the variant’s presence in known cancer hotspots or active binding sites. These criteria are combined by summing over the scores for all applicable scoring criteria. Scores exceeding 3 indicate an oncogenic or likely oncogenic classification, while scores falling below -3 indicate a benign or likely benign classification.
In this webcast, we discuss how each of these scoring criteria are combined to obtain an oncogenicity classification. This includes a discussion of the considerations taken into account during the development of this scoring system and a detailed analysis of several example mutations to illustrate the system in practice.
CNV Annotations: a crucial step in your variant analysisGolden Helix
Since the development of our NGS-based CNV solutions for VarSeq and SVS, we've generated a long list of content demonstrating simple workflows to help isolate clinically relevant events for a given sample. However, it's just as important to talk about the exclusionary filters that help remove any extraneous CNVs from the analysis.
Golden Helix stands alone in our delivery of multiple methods for filtering down to top-quality, rare, and clinically relevant variants. This webcast will focus on the application of the various CNV annotations, discussing their purpose and usability in quickly removing CNVs with high-population frequency, duplicated regions inherent to the human genome, benign events, and events known in healthy individuals.
Please join us in an exploration of VarSeq's unique CNV annotation capabilities to see how users can overcome the challenges of NGS-based CNV detection.
What will you learn in this webcast?
Initial assessment of sample and CNV event quality
General review and understanding of various CNV annotations in VarSeq
The application of CNV annotations to eliminate common and benign CNVs
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline WorkflowGolden Helix
Golden Helix has been in close communication with the publishers of the ACMG guidelines and the ClinGen group to receive expert advice on how to interpret CNVs called on NGS data. These guidelines provide a robust set of rules for interpreting intragenic deletions and duplications, which is summarized into an intricate decision tree that is broken down into 80 distinct criteria. This complexity is further compounded by many important caveats, exceptions, and considerations known to many in the CNV clinical workspace but are not mentioned in the published guidelines. Fortunately, Golden Helix has spent long hours reading the guidelines, watching the webinars, reading the supplementary material, and working with collaborators to develop a comprehensive workflow to guide you through your clinical interpretation of CNVs. Herein, we are excited to cover more details into this novel ACMG CNV guideline interpretation workflow and demonstrate how intuitive this feature can be for your clinical pipeline. Specifically, we will cover:
The intricacies of the ACMG CNV Sample auto classifier
Unique annotations and algorithms
Adjustable metrics and parameters in the VSClinical ACMG interface
Rendering clinical reports
Why should your accounting or advisory firm do blogging? Where does blogging fit into your overall marketing approach? How do you measure its effectiveness? What results are firms getting?
Everyone has a skeleton in the closet, even most famous #writers have, no matter how many bestsellers they wrote or prizes they won.
For example, if you have read only the works of this famous writer, you never guess that…
Check out our #infographic and related blog post for more details goo.gl/1TP8FR
Do you have your eye on a plush corner office? Chances are, you'll need more than ambition alone to land a top spot in the C-Suite.
If you've ever wondered what factors contribute to CEO status and success, check out this infographic. It details a few of the most common characteristics of modern CEOs, including personality traits, education credentials and rates of succession.
Read more: http://on.mash.to/19MEgeq
Cool Genes: The Search for a Cure Using Genomics, Big Data, and Docker - Jame...Docker, Inc.
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to using genomic and other -omic generated information to provide a greater understanding of the underlying biological defects that cause diseases and disorders. The human genome has over 3 billion nucleotide base pairs residing in our 23 pairs of chromosomes, each of which has up to thousands of genes. Talk about looking into The Matrix! The bioinformatics industry is undergoing a sea change, driven by advances in biological research and gains in computational power that accelerates the ability to find treatments and cures. While inexpensive compute infrastructure made this work possible, managing those enormous workloads was a massive headache, until science found a cure: Docker! This talk will describe how TGen uses Docker and the Docker storage plugins API to run a large-scale, big data compute cluster to push the limits of biological science. You will learn:
- How TGen uses bioinformatics to predict disease behavior and hypothesize a cure
- How to package bioinformatics workloads into Docker containers How to orchestrate elastic compute clusters at scale
- How to manage big data workloads using the Docker plugins API v2
How novel compute technology transforms life science researchDenis C. Bauer
Unprecedented data volumes and pressure on turnaround time driven by commercial applications require bioinformatics solutions to evolve to meed these new demands. New compute paradigms and cloud-based IT solutions enable this transition. Here I present two solution capable of meeting these demands for genomic variant analysis, VariantSpark, as well as genome engineering applications, GT-Scan2.
VariantSpark classifies 3000 individuals with 80 Million genomic variants each in under 30 minutes. This Hadoop/Spark solution for machine learning application on genomic data is hence capable to scale up to population size cohorts.
GT-Scan2, identifies CRISPR target sites by minimizing off-target effects and maximizing on-target efficiency. This optimization is powered by AWS Lambda functions, which offer an “always-on” web service that can instantaneously recruit enough compute resources keep runtime stable even for queries with several thousand of potential target sites.
Forensics: Human Identity Testing in the Applied Genetics Groupnist-spin
"Forensics: Human Identity Testing in the Applied Genetics Group" presentation at the Standards for Pathogen Identification via NGS (SPIN) workshop hosted by National Institute for Standards and Technology October 2014 by Peter Vallone, PhD from NIST.
VariantSpark: applying Spark-based machine learning methods to genomic inform...Denis C. Bauer
Genomic information is increasingly used in medical practice giving rise to the need for efficient analysis methodology able to cope with thousands of individuals and millions of variants. Here we introduce VariantSpark, which utilizes Hadoop/Spark along with its machine learning library, MLlib, providing the means of parallelisation for population-scale bioinformatics tasks. VariantSpark is the interface to the standard variant format (VCF), offers seamless genome-wide sampling of variants and provides a pipeline for visualising results.
To demonstrate the capabilities of VariantSpark, we clustered more than 3,000 individuals with 80 Million variants each to determine the population structure in the dataset. VariantSpark is 80% faster than the Spark-based genome clustering approach, ADAM, the comparable implementation using Hadoop/Mahout, as well as Admixture, a commonly used tool for determining individual ancestries. It is over 90% faster than traditional implementations using R and Python. These benefits of speed, resource consumption and scalability enables VariantSpark to open up the usage of advanced, efficient machine learning algorithms to genomic data.
The package is written in Scala and available at https://github.com/BauerLab/VariantSpark.
How to Create CRISPR-Edited T Cells More Efficiently for Tomorrow's Cell Ther...InsideScientific
Ian Foster and Steven Loo-Yong-Kee discuss Artisan Bio's STAR-CRISPR system for optimized gene editing in cell therapy, with a focus on the genetifc modification of T cells for cancer immunotherapy.
Cell therapy is an emerging field with great promise for the treatment of various diseases. One of the most exciting areas of cell therapy is the use of T cells that have been genetically modified to recognize and kill cancer cells. While the use of T cells for cancer immunotherapy has tremendous promise, there is still room for improvement. The efficiency, expansion, and functionality of T cells can be enhanced by genetic modification using the STAR-CRISPR system.
Artisan Bio is a biotechnology company focused on developing a CRISPR-mediated editing platform to improve the efficacy and safety of cell therapy products. In this webinar, we will provide a comprehensive overview of Artisan Bio’s STAR-CRISPR system, which is designed to improve the specificity and efficiency of gene editing for cell therapies. We will explain the system’s key components and how we are using a risk-based approach to optimize and validate the editing platform. The webinar will focus on Artisan Bio’s approach to building T cell OS/APPS through iterative improvements to achieve best-in-class editing capabilities and improved cell health metrics.
Key Topics Include:
- Learn about Artisan Bio’s proprietary high-performance STAR-CRISPR system for improving the specificity and efficiency of gene editing for cell therapies
- Explore Artisan Bio’s risk-based, systems approach to technology development, including how to implement Design of Experiments (DoE) and Quality by Design (QbD) principles to optimize and validate any process
- Case study of the application of QbD to Artisan Bio’s STAR-CRISPR platform to edit T cells for cancer immunotherapy with preliminary data showing improved efficacy, expansion, and functionality
Next generation sequencing & microarray-- Genotypic TechnologyGenotypic Technology
Greetings from Genotypic Technology, Bangalore (www.genotypic.co.in). We are a 13 year old genomics and bioinformatics company ( 65+ employees, Service. Products and R & D) based in Bangalore, India, primarily working on applications of Microarrays and Next Generation Sequencing in Human Health and Disease, including in Molecular Diagnostics, Prognosis, Therapeutics, Vaccine Research, Basic Science Research, Veterinary Science, Agriculture, Industrial Biotechnology, Microbial Genetics and more.
Our major strength is in customized genomics solutions, particularly in your field, we can develop panel of markers for specific diseases, optimize, validate and help commercialize on open platforms or specific instrument platforms- in microarrays and sequencing based methods/ assays. We can also use genomic markers to aid in treatment of specific disease using personalized medicine approaches. All this can be done on a comprehensive end-to-end manner in our company as we have a very good blend of molecular biology and bioinformatics with totally 6 Ph.Ds. We work closely with Agilent's R &D as their partner.
Next generation genomics: Petascale data in the life sciencesGuy Coates
Keynote presentation at OGF 28.
The year 2000 saw the release of "The" human genome, the product of a the combined sequencing effort of the whole planet. In 2010, single institutions are sequencing thousands of genomes a year, producing petabytes of data. Furthermore, many of the large scale sequencing projects are based around international collaboration and consortia. The talk will explore how Grid and Cloud technologies are being used to share genomics data around the planet, revolutionizing life science research.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
State of ICS and IoT Cyber Threat Landscape Report 2024 previewPrayukth K V
The IoT and OT threat landscape report has been prepared by the Threat Research Team at Sectrio using data from Sectrio, cyber threat intelligence farming facilities spread across over 85 cities around the world. In addition, Sectrio also runs AI-based advanced threat and payload engagement facilities that serve as sinks to attract and engage sophisticated threat actors, and newer malware including new variants and latent threats that are at an earlier stage of development.
The latest edition of the OT/ICS and IoT security Threat Landscape Report 2024 also covers:
State of global ICS asset and network exposure
Sectoral targets and attacks as well as the cost of ransom
Global APT activity, AI usage, actor and tactic profiles, and implications
Rise in volumes of AI-powered cyberattacks
Major cyber events in 2024
Malware and malicious payload trends
Cyberattack types and targets
Vulnerability exploit attempts on CVEs
Attacks on counties – USA
Expansion of bot farms – how, where, and why
In-depth analysis of the cyber threat landscape across North America, South America, Europe, APAC, and the Middle East
Why are attacks on smart factories rising?
Cyber risk predictions
Axis of attacks – Europe
Systemic attacks in the Middle East
Download the full report from here:
https://sectrio.com/resources/ot-threat-landscape-reports/sectrio-releases-ot-ics-and-iot-security-threat-landscape-report-2024/
Generating a custom Ruby SDK for your web service or Rails API using Smithyg2nightmarescribd
Have you ever wanted a Ruby client API to communicate with your web service? Smithy is a protocol-agnostic language for defining services and SDKs. Smithy Ruby is an implementation of Smithy that generates a Ruby SDK using a Smithy model. In this talk, we will explore Smithy and Smithy Ruby to learn how to generate custom feature-rich SDKs that can communicate with any web service, such as a Rails JSON API.
Kubernetes & AI - Beauty and the Beast !?! @KCD Istanbul 2024Tobias Schneck
As AI technology is pushing into IT I was wondering myself, as an “infrastructure container kubernetes guy”, how get this fancy AI technology get managed from an infrastructure operational view? Is it possible to apply our lovely cloud native principals as well? What benefit’s both technologies could bring to each other?
Let me take this questions and provide you a short journey through existing deployment models and use cases for AI software. On practical examples, we discuss what cloud/on-premise strategy we may need for applying it to our own infrastructure to get it to work from an enterprise perspective. I want to give an overview about infrastructure requirements and technologies, what could be beneficial or limiting your AI use cases in an enterprise environment. An interactive Demo will give you some insides, what approaches I got already working for real.
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
GraphRAG is All You need? LLM & Knowledge GraphGuy Korland
Guy Korland, CEO and Co-founder of FalkorDB, will review two articles on the integration of language models with knowledge graphs.
1. Unifying Large Language Models and Knowledge Graphs: A Roadmap.
https://arxiv.org/abs/2306.08302
2. Microsoft Research's GraphRAG paper and a review paper on various uses of knowledge graphs:
https://www.microsoft.com/en-us/research/blog/graphrag-unlocking-llm-discovery-on-narrative-private-data/
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Slack (or Teams) Automation for Bonterra Impact Management (fka Social Soluti...Jeffrey Haguewood
Sidekick Solutions uses Bonterra Impact Management (fka Social Solutions Apricot) and automation solutions to integrate data for business workflows.
We believe integration and automation are essential to user experience and the promise of efficient work through technology. Automation is the critical ingredient to realizing that full vision. We develop integration products and services for Bonterra Case Management software to support the deployment of automations for a variety of use cases.
This video focuses on the notifications, alerts, and approval requests using Slack for Bonterra Impact Management. The solutions covered in this webinar can also be deployed for Microsoft Teams.
Interested in deploying notification automations for Bonterra Impact Management? Contact us at sales@sidekicksolutionsllc.com to discuss next steps.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
Dev Dives: Train smarter, not harder – active learning and UiPath LLMs for do...UiPathCommunity
💥 Speed, accuracy, and scaling – discover the superpowers of GenAI in action with UiPath Document Understanding and Communications Mining™:
See how to accelerate model training and optimize model performance with active learning
Learn about the latest enhancements to out-of-the-box document processing – with little to no training required
Get an exclusive demo of the new family of UiPath LLMs – GenAI models specialized for processing different types of documents and messages
This is a hands-on session specifically designed for automation developers and AI enthusiasts seeking to enhance their knowledge in leveraging the latest intelligent document processing capabilities offered by UiPath.
Speakers:
👨🏫 Andras Palfi, Senior Product Manager, UiPath
👩🏫 Lenka Dulovicova, Product Program Manager, UiPath
UiPath Test Automation using UiPath Test Suite series, part 3DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 3. In this session, we will cover desktop automation along with UI automation.
Topics covered:
UI automation Introduction,
UI automation Sample
Desktop automation flow
Pradeep Chinnala, Senior Consultant Automation Developer @WonderBotz and UiPath MVP
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
2. 2
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
From Whence We Came…
ATGCCGTTT…
CCGGTTAAT…
GAATTGCAG…
6:A2567C
12:C123T
20:T4678A
30-40TB
˜5TB
600GB
˜20GB
3. 3
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Genomic Big Data
Large amounts of data generated in genomics; multiple
samples, size of data, etc
Integration of digital data to enrich context of samples;
DNA, RNA, methylation, time courses, spatial
distributions with samples, …
Fusion of digital data and categorical data; combination
rules (categories), extraction from unstructured inputs,
…
Tools and techniques appropriate for resultant data
sets; visualization, model building, exploration, …
Advances require data mining rather than the one-at-a-
time hypothesis testing approaches of today
4. 4
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Genomic Big Data and Personal Genome Information
PERSONAL SEQUENCE
(owned by individual/doctor)
Issued: 01 MAR 07 Recommended next check: 28 FEB 10
PGI id: 5910322 – 61215923014
RISK VARIANTS
(approved for clinical use)
Human Genome
Clinical studies Populations
SequencingFunctional annotation
3: 12,300 3: 12,400 ( kb )
PPARg
GENOMIC ANNOTATION
(in public domain)
Variant: C3 : 12,450,610 : T0.7/C0.3 :
PPARG : Pro/Leu :
Medical
consequence:
Associated with severe insulin
resistance, diabetes mellitus,
hypertension
Pharmacological
consequence:
Resistant to thiazolidinediones
CLINICAL DECISION
Consultation
Consent
Clinical assessment
Selected risk
information
5. 5
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Sequencing a 17-member three-generation
pedigree.
– Ultra deep sequencing improves sensitivity
– Leveraging inheritance information improves
accuracy
– Data and results made publicly available
Identifying ultra accurate genomic variants is
enabling rapid improvements in technology
and software
This data will allow us to assess accuracy for
many FDA submissions
We are collaborating with NIST & CDC to
develop a public resource for quantifying
sequencing accuracy
Platinum Genomes as a Truth Reference
Creating a catalogue of highly-accurate SNPs, indels & SVs
6. 6
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Reduction from 40 Q-scores to 8 Q-scores becoming accepted
Sequencing output is still increasing exponentially therefore further
compression is likely to be required
Platinum genome work suggest ~95% of genome is consistently called (this
95% is known as the platinum regions)
Regions which are reliably called may not need 8 Q-scores resolution
– we can reduce “well
sequenced” regions to 2 Q-
scores
Start with 8 Q-score bam file:
– Reduce the platinum regions
to 2 Q-scores (keep non-
platinum at 8 Q-scores)
– Reduce the platinum regions
to 1 Q-score
– Whole genome
2 Q-score
– Reduce platinum region to 2
Q-scores but also keep
original Q-scores of
mismatches (MM) and
anomalous reads
– ~40Gb (20Gb CRAM)
Data Reduction Via Vertical Compression (NA12882)
Build Total SNPs
(>Q20)
SNPs diff
genotype
(>Q20)
Not called in
Q-score
compressed
build
(>Q20)
Not called in 8
Q-score build
(>Q20)
8 Q-score 3,735,575
(3,627,165)
- - -
8 Q-score
technical
replicate
3,734,849
(3,626,485)
45,584
(22,400)
80,131 (29,211) 79,405 (28,845)
Platinum
Genome 2 Q-
score
3,732,568
(3,620,612)
3,255 (161) 3417 (63) 410 (127)
Platinum
Genome 1 Q-
score
3,764,928
(3,626,468)
4002 (584) 2605 (75) 31,958 (2964)
Whole Genome
2 Q-score
3,712,636
(3,598,400)
25,175 (1912) 24,237 (166) 1298 (112)
Platinum 2 q-
score keep MM
and anom.
reads
3,735,684
(3,627,226)
197 (123) 142 (35) 251 (102)
7. 7
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Faster Data – DNA to Result in <2 Days
12 core server
64Gb RAM
Sequence Analyze AnnotateSample
27 hr 8 hr
HiSeq2500 Isaac analysis overnight
40 hr
Fast turnaround is required for clinical applications
4.5 hr
PCR Free library
8. 8
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
WGS reveals somatic mutations in TERT
gene promoter of melanoma patients
Form a novel transcription factor binding
motif
Recurrence in melanoma is as high as
any known coding mutation
Importance of Non-coding Mutations – Bigger Data!
-200 -100
TERT gene
0 +100 +200
Gene (mutation) Incidence in
melanoma
TERT (promoter) 52%
BRAF (V600E) 53%
CDKN2A 50%
NRAS (Q61R) 28%
TERT (coding) 1%
Horn et al. & Huang et al., Science 2013
10. 10
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Surveillance of Leukaemia (CLL) – More Data Complexity!
0 6463 65 6662
Event
Timeline
Sequencing
Birth DeathTreatmentDiagnosis TreatmentTreatment
0
50
100
150
200
250
a b c d e
NORMAL
CLASS 4
CLASS 3
CLASS 2
CLASS 1
Time points
Abundance
Changing
subclonal
populations
0
1
2
3
4
5
c
NO
CL
CL
CL
CL
“Remission” has
disease
Schuh et al., Oxford
12. 12
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Utility Requires Complex Composite Information
iPad
Plug and Play
Cloud
Allele Frequency
in populations
www.1000genomes.org
Medical/Risk data
(with expert review)
Hgmd, pharmgkb
Genetic Variants
dbSNP
Functional Effects
ensembl.org,
genome.ucsc.edu,
encode.org
Disease association
genome.gov
ANNOTATED
GENOME
( gVCF)
<1Gbyte
Ancestry
Tissue type
Risk
Carrier status
Diagnosis
Drug
response
Annotate DisseminateInterpret
13. 13
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Apps
Public Genomic Databases
Users
EMR
Support & Engineering
Instruments
Genomic Big Data Ecosystems
14. 14
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Genomic Big Data Status
Researcher
Treatment choice
Clinician
Patient
Knowledge
Information
15. 15
COMPANY CONFIDENTIAL – INTERNAL USE ONLY
Challenges for this Meeting to Address
What data frameworks and models
are required?
How will genomes (DNA, RNA,
methylation states, etc) be
aggregated and compared?
How will collaboration and data
sharing evolve?
Where will the technology go and
how must the community respond
to lever the benefits
Brainstorming of ideas
Sessions from groups that have
experiences from many fields
Next steps!!
Actively participate and enjoy the entire
experience!
